HopeStage
Back to all studies
CompletedNCT04781998

Liraglutide for weight-related health in forensic psychiatric care

About this titleRead the official source — NCT04781998
Medication studyAges 18–65DenmarkMental health
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
RoskildeSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: July 1, 2021
Recruitment status
Completed
Enrollment listed in the registry
24
Sponsor
Anders Fink-Jensen, MD, DMSci
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Denmark
Age range
From 18 Years to 65 Years
Official registry ID
NCT04781998
Official title
Show the full official title

Is Pharmacological Treatment With the Glucagon-like Peptide-1 Receptor Agonist Liraglutide 3mg (Saxenda®) Once-daily a Viable Treatment for Weight Management in Forensic Psychiatry Patients? A Feasibility Study.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Roskilde

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Anders Fink-Jensen, MD, DMSci.

Did this study involve medication?

Yes. The study involved medication, including liraglutide 3 mg (Saxenda®) once-daily.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies